The IQVIA Institute recently released a report that highlights several intriguing findings regarding the global launch of novel active substances (NASs) in 2022. While there was a slight decline compared to the previous two years, with 64 NASs launched, it marks a return to pre-COVID-19 levels. The report also sheds light on the therapeutic areas that have seen a significant increase in new launches over the past five years, namely oncology, neurology, and immunology, accounting for almost half of all launches. Additionally, the study emphasizes the importance of infectious disease treatments, including those for COVID-19, as well as other viruses, bacteria, fungi, and parasites. These treatments have constituted a notable portion of NAS launches in the past decade, with certain fluctuations observed from year to year. The findings from this report provide valuable insights into the evolving landscape of pharmaceutical innovations and the impact of recent global health challenges on drug development and launches.1
Click here to access the report.
References
- Global Trends in R&D 2023. (n.d.). IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
